Research program

Current situation

Even today, despite the constant improvement of multiple myeloma therapies with new, more effective molecules, multiple myeloma remains incurable for the vast majority of patients with this terrible disease. For the majority of patients, the conceivable survival is on average at least 5 years. In contrast, there is a group of patients (approximately 25-30%) who have a poorer-risk disease, with survival of about 2 to 3 years only. Although this is a heterogeneous disease, certain factors are associated with a poor prognosis. Several recurrent genetic abnormalities such as the del17p13, the t(4;14)(p16;q32), t(14;16)(q32;q23) and t(14;20)(q32;q12), and chromosome Experience of Hôpital Maisonneuve-Rosemont in allogeneic hematopoietic stem cell transplantation in the treatment of multiple myeloma

Over the past 20 years, the department of hematology and oncology at Hôpital Maisonneuve-Rosemont has developed significant expertise in allogeneic hematopoietic stem cell transplantation in the treatment of hematological cancers. More specifically in multiple myeloma, experience was first built with myeloablative preparation regimes that have been associated with higher toxicity Le Blanc, Bone Marrow Transplant 2001. In the past 15 years, nonmyeloablative preparation regimes have allowed for significantly reducing certain associated toxicities. Between 2001 and 2010, we conducted a phase II study in 93 newly diagnosed multiple myeloma patients who were eligible for transplant (hematopoietic stem cell transplantation team of Hôpital Maisonneuve-Rosemont as well as the proximity of Center of Excellence for Cellular Therapy (CETC) will facilitate collaboration for this kind of project.